Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial -

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
Information type: Randomised controlled trials
Source: The Lancet Haematology
Specialities: Cancers | Haematological disorders | Paediatric and neonatal medicine
Summary
Authors suggest that patients with low minimal residual disease (MRD) had favourable outcomes without requiring stem-cell transplantation, whereas those with high MRD benefit from stem-cell transplantation; targeted therapies might offer further improvements for these patients.
UKMi comment
A related commentary discusses this research. It details that as the outcome data from the ALLR3 trial continue to mature, key observations that affect clinical practice continue to be revealed. With the advent of novel immunotherapies and improvements in stem cell transplant, including haplo-identical transplantation, the therapeutic landscape for acute lymphoblastic leukaemia has developed significantly.
Related links: Editorial